Adenoid Cystic Cancer News and Articles

Return to Library

Recent Adenoid Cystic Cancer News and Articles

• Research on Lymphoid Tissue Detailed by Investigators at Emory University
• Researchers from Central Hospital Detail Findings in Cardiovascular and Thoracic Surgery
• Emory University Details Research in Cancer
• New Otolaryngology Study Findings Have Been Reported from Greater Baltimore Medical Center
• Studies from Tubingen University Hospital in the Area of Clinical Oncology Described
• Studies Conducted at Shanghai Jiao-Tong University on Lymphoid Tissue Recently Published

---

Researchers from University of Texas Report Recent Findings in Cancer Biology

2012 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Cancer Biology have been published. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "Adenoid cystic carcinoma (ACC), the second most frequent malignancy of the major and minor salivary glands, comprise of approximately 15-23% of all carcinomas at these locations. ACC is uniquely formed of dual epithelial and myoepithelial cells that give rise to different phenotypic patterns."

Our news journalists obtained a quote from the research from the University of Texas, "We hypothesize that the dual myoepithelial/ epithelial composition of ACCs underlie their biological heterogeneity and may impact on their therapeutic management. A recurrent reciprocal translocation of t(6;9)(q22-23; p23-24) resulting in fusion gene partners comprising MYB gene the transcription factor NFIB has been reported in ACC of breast, salivary, lachrymal and ceruminal glands. In fusion positive and a subset of fusion negative ACCs, high expression of the transcript Myb was found. However, the role of Myb protein expression and the potential effect on the downstream targets have not been investigated. To investigate the biological and prognostic significance of use of elevated levels of Myb and its downstream target genes (c-kit, cox-2, bcl-2), we analyzed, by immunohistochemistry, the protein expression of these genes in 156 ACCs. We have found that 55% of ACCs have increased Myb expression mainly confined to myoepithelial cells. We validated Myb expression on a large cohort of ACCs (156 patients). Although no significant effects of the individual Myb and downstream targets c-kit, bcl-2 and cox-2 on survival was noticed, the combinations survival curve for Myb+/c-kit+/cox-2+ showed better survival than combination Myb-/c-kit+/cox-2+."

According to the news editors, the research concluded: "Myb may serve as a new target for the management of this disease, and future therapeutic trials of these tumors may be better based on biomarker stratification and the cellular composition of these tumors."

For more information on this research see: Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer Biology & Therapy, 2011;12(7):569-73.

The news correspondents report that additional information may be obtained from D. Bell, Dept. of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Keywords for this news article include: Texas, Houston, Genetics, Oncology, Immunology, United States, Cancer Biology, Lymphoid Tissue, Adenoid Cystic Cancer, Adenoid Cystic Carcinoma, Hemic and Immune Systems, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC